NBIX insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 100% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 15 officers and directors who sold. 21 are left out

Left out: Kevin Gorman, Kyle Gano, Gary Lyons, Eiry Roberts, Eric Benevich, Darin Lippoldt, William Rastetter, Matt Abernethy, Richard Pops, Julie Cooke, Jude Onyia, Stephen Sherwin, George Morrow, Ingrid Delaet, David Boyer, Johanna Mercier, Leslie Norwalk, Shalini Sharp, Christine Poon, Andrew Ratz and Sanjay Keswani (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Kevin Gorman

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$37.8MDisclosed plan

Julie Cooke

Chief Human Resources Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.8MDisclosed plan

Kyle Gano

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.9MDisclosed plan

Darin Lippoldt

Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.2MDisclosed plan

Stephen Sherwin

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.1MDisclosed plan

All 15 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 14, 20262 executives sold 3.1K shares ($493K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Matt Abernethy Chief Financial Officer	2,311	$157.20	n/a	n/a	Sep 14, 2026	Sep 15, 2026
David Boyer Chief Corp. Affairs Officer	826	$157.45	n/a	n/a	Sep 14, 2026	Sep 15, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Neurocrine Biosciences Inc CEO selling stock?

Yes. Kyle Gano sold 37K shares ($4.9M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Neurocrine Biosciences Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any Neurocrine Biosciences Inc insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold15 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Kevin Gorman Director	$37.8M 245K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Julie Cooke Chief Human Resources Officer	$5.8M 37K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Kyle Gano Chief Executive Officer, Director	$4.9M 37K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Darin Lippoldt Chief Legal Officer	$4.2M 24K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Stephen Sherwin Director	$4.1M 25K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Ingrid Delaet Chief Regulatory Officer	$3.7M 21K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jude Onyia Chief Scientific Officer	$3.5M 22K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
William Rastetter Director	$2.7M 18K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Richard Pops Director	$2.4M 15K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Gary Lyons Director	$2.3M 15K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
George Morrow Director	$2.2M 15K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Leslie Norwalk Director	$2.0M 13K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Eric Benevich Chief Commercial Officer	$1.2M 8.1K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
David Boyer Chief Corp. Affairs Officer	$739K 4.7K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Matt Abernethy Chief Financial Officer	$363K 2.3K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 21 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Kevin Gorman

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kevin Gorman are complete.

Director

n/a

−245K

n/a

Vesting, gifts, unvested awards and holding lines for Kevin Gorman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Gorman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−51Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
112,644	$133.84	Feb 13, 2034	$2.7M
6,610	$120.56	May 21, 2035	$244K
5,248	$155.83	May 27, 2036	$8K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Kyle Gano

Chief Executive Officer, Director

n/a

−37K

n/a

Vesting, gifts, unvested awards and holding lines for Kyle Gano

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kyle Gano are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−17Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
45,058	$133.84	Feb 13, 2034	$1.1M
13,344	$122.21	Nov 1, 2034	$470K
104,736	$117.18	Feb 12, 2035	$4.2M
114,830	$124.12	Feb 13, 2036	$3.8M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Gary Lyons

Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for Gary Lyons

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gary Lyons are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,982	$139.43	May 22, 2034	$54K
3,305	$120.56	May 21, 2035	$122K
2,624	$155.83	May 27, 2036	$4K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Eiry Roberts

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Eiry Roberts

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eiry Roberts are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,147	$102.90	Feb 6, 2030	$935K
48,199	$117.63	Feb 8, 2031	$1.9M
60,005	$79.02	Jan 31, 2032	$4.7M
965	$103.52	Feb 13, 2033	$52K
51,567	$103.52	Feb 13, 2033	$2.8M
747	$133.84	Feb 13, 2034	$18K
21,782	$133.84	Feb 13, 2034	$514K
27,770	$136.69	Dec 17, 2034	$576K
853	$117.18	Feb 12, 2035	$34K
42,408	$117.18	Feb 12, 2035	$1.7M
10,087	$124.12	Feb 13, 2036	$336K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Eric Benevich

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Eric Benevich are complete.

Chief Commercial Officer

n/a

−8.1K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Benevich

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Benevich are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−17Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
39,426	$133.84	Feb 13, 2034	$931K
33,881	$79.02	Jan 31, 2032	$2.7M
26,292	$81.49	Feb 5, 2028	$2.0M
42,805	$117.18	Feb 12, 2035	$1.7M
36,287	$124.12	Feb 13, 2036	$1.2M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Darin Lippoldt

Chief Legal Officer

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Darin Lippoldt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Darin Lippoldt are complete; balances and unit counts will be added when the check is finished.

−365gifted (net of own trusts)

−12Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
43,372	$79.02	Jan 31, 2032	$3.4M
40,552	$133.84	Feb 13, 2034	$957K
38,252	$117.18	Feb 12, 2035	$1.5M
34,909	$124.12	Feb 13, 2036	$1.2M
4,965	$81.49	Feb 5, 2028	$377K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

William Rastetter

Director

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for William Rastetter

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Rastetter are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Matt Abernethy

Chief Financial Officer

n/a

−2.3K

n/a

Vesting, gifts, unvested awards and holding lines for Matt Abernethy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matt Abernethy are complete; balances and unit counts will be added when the check is finished.

−2.2Kgifted (net of own trusts)

−13Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
45,058	$133.84	Feb 13, 2034	$1.1M
45,538	$117.18	Feb 12, 2035	$1.8M
44,095	$124.12	Feb 13, 2036	$1.5M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Richard Pops

Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for Richard Pops

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Pops are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Julie Cooke

Chief Human Resources Officer

n/a

−37K

n/a

Vesting, gifts, unvested awards and holding lines for Julie Cooke

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Julie Cooke are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−11Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,129	$81.05	Feb 7, 2029	$621K
28,161	$133.84	Feb 13, 2034	$665K
29,600	$117.18	Feb 12, 2035	$1.2M
27,100	$124.12	Feb 13, 2036	$903K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Jude Onyia

Chief Scientific Officer

n/a

−22K

n/a

Vesting, gifts, unvested awards and holding lines for Jude Onyia

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jude Onyia are complete; balances and unit counts will be added when the check is finished.

−8Kgifted (net of own trusts)

−19Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
54,069	$133.84	Feb 13, 2034	$1.3M
54,645	$117.18	Feb 12, 2035	$2.2M
13,268	$84.74	Nov 29, 2031	$965K
55,119	$124.12	Feb 13, 2036	$1.8M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Stephen Sherwin

Director

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for Stephen Sherwin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stephen Sherwin are complete; balances and unit counts will be added when the check is finished.

−1Kgifted (net of own trusts)

George Morrow

Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for George Morrow

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for George Morrow are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Ingrid Delaet

Chief Regulatory Officer

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Ingrid Delaet

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ingrid Delaet are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−16Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
28,161	$133.84	Feb 13, 2034	$665K
7,478	$103.52	Feb 13, 2033	$403K
34,153	$117.18	Feb 12, 2035	$1.4M
31,234	$124.12	Feb 13, 2036	$1.0M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

David Boyer

Chief Corp. Affairs Officer

n/a

−4.7K

n/a

Vesting, gifts, unvested awards and holding lines for David Boyer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Boyer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−11Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,977	$133.84	Feb 13, 2034	$731K
34,153	$117.18	Feb 12, 2035	$1.4M
31,234	$124.12	Feb 13, 2036	$1.0M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Johanna Mercier

Director

n/a

Vesting, gifts, unvested awards and holding lines for Johanna Mercier

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Johanna Mercier are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,982	$139.43	May 22, 2034	$54K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Leslie Norwalk

Director

n/a

−13K

n/a

Vesting, gifts, unvested awards and holding lines for Leslie Norwalk

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Leslie Norwalk are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
557	$92.35	May 19, 2031	$36K
2,140	$139.43	May 22, 2034	$39K
3,305	$120.56	May 21, 2035	$122K
2,624	$155.83	May 27, 2036	$4K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Shalini Sharp

Director

n/a

Vesting, gifts, unvested awards and holding lines for Shalini Sharp

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shalini Sharp are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,982	$139.43	May 22, 2034	$54K
3,305	$120.56	May 21, 2035	$122K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Christine Poon

Director

n/a

Vesting, gifts, unvested awards and holding lines for Christine Poon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christine Poon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,982	$139.43	May 22, 2034	$54K

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Andrew Ratz

Chief Technical Operations Off

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Ratz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Ratz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,664	$150.10	Feb 3, 2035	$20K
17,724	$150.10	Feb 3, 2035	$130K
805	$124.12	Feb 13, 2036	$27K
31,348	$124.12	Feb 13, 2036	$1.0M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Sanjay Keswani

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Sanjay Keswani

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sanjay Keswani are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−3.8Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
70,101	$124.56	Jun 2, 2035	$2.3M
35,827	$124.12	Feb 13, 2036	$1.2M

Estimate: options held × ($157.45 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Holdings and share of stake for Neurocrine Biosciences Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$77.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $77.9M across 501,949 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $77.9M · 100%

Taxes

$43K of sales (0.1%) cite tax obligations in their footnotes, $43K of them also under a plan. Separately, 171,086 shares ($22.5M) were withheld by the company for taxes, which isn't a market sale. Example: Kyle Gano, Nov 4, 2025

Charitable gifts · 12K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Kevin Gorman Director	245K	$37.8M	100%	49%	May 19, 2026 to May 19, 2026
Julie Cooke Chief Human Resources Officer	37K	$5.8M	100%	7%	Jun 2, 2026 to Jun 2, 2026
Kyle Gano Chief Executive Officer, Director	37K	$4.9M	100%	6%	Nov 4, 2025 to Jan 16, 2026
Darin Lippoldt Chief Legal Officer	24K	$4.2M	100%	5%	Dec 8, 2025 to Jul 9, 2026
Stephen Sherwin Director	25K	$4.1M	100%	5%	Jun 5, 2026 to Jun 5, 2026
Ingrid Delaet Chief Regulatory Officer	21K	$3.7M	100%	5%	May 29, 2026 to Jul 10, 2026
Jude Onyia Chief Scientific Officer	22K	$3.5M	100%	4%	May 27, 2026 to Jun 1, 2026
William Rastetter Director	18K	$2.7M	100%	4%	Nov 5, 2025 to Nov 5, 2025
Richard Pops Director	15K	$2.4M	100%	3%	May 15, 2026 to May 15, 2026
Gary Lyons Director	15K	$2.3M	100%	3%	Dec 3, 2025 to Dec 3, 2025
George Morrow Director	15K	$2.2M	100%	3%	Nov 25, 2025 to Nov 25, 2025
Leslie Norwalk Director	13K	$2.0M	100%	3%	Dec 15, 2025 to Jul 28, 2026
Eric Benevich Chief Commercial Officer	8.1K	$1.2M	100%	2%	Nov 28, 2025 to Sep 9, 2026
David Boyer Chief Corp. Affairs Officer	4.7K	$739K	100%	0.9%	May 26, 2026 to Sep 14, 2026
Matt Abernethy Chief Financial Officer	2.3K	$363K	100%	0.5%	Sep 14, 2026 to Sep 14, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$5.8M	$5.8M	$0	$0
Dec 2025	$3.9M	$3.9M	$0	$0
Jan 2026	$4.8M	$4.8M	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$43.5M	$43.5M	$0	$0
Jun 2026	$13.6M	$13.6M	$0	$0
Jul 2026	$5.4M	$5.4M	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$826K	$826K	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 15 insiders sold; the average is 14 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	502K	15	$77.9M
Oct 13, 2025 1 year earlier	502K	12	$67.5M
Oct 13, 2024 2 years earlier	949K	17	$127M
Oct 14, 2023 3 years earlier	482K	15	$53.7M
Oct 14, 2022 4 years earlier	180K	13	$16.0M
Oct 14, 2021 5 years earlier	515K	11	$56.2M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty21 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Neurocrine Biosciences Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,228 filings on record, 83 filed in the 12-month period, and how we read them

All 1,228 Forms 3, 4 and 5 on record for Neurocrine Biosciences Inc (SEC CIK 914475), filed from Sep 10, 2002 to Oct 7, 2026; 83 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages. 3 filings were left out because Neurocrine Biosciences Inc filed them as an owner of another company's stock. 17 older filings exist only on paper and could not be read.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (26)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Malcolm Lloyd-Smith	Feb 8, 2023	42,337 shares, last reported balance as of Feb 8, 2023
Dimitri Grigoriadis	Feb 2, 2022	82,273 shares, last reported balance as of Oct 7, 2021
Haig Bozigian	Mar 29, 2021	157,651 shares, last reported balance as of Feb 8, 2021
Alfred Sandrock	May 23, 2019	No balance on record
Corinne Nevinny	May 25, 2018	43,283 shares, last reported balance as of May 7, 2018
Christopher OBrien	Feb 7, 2018	55,946 shares, last reported balance as of Feb 6, 2018
Joseph Mollica	Jun 8, 2017	56,042 shares, last reported balance as of Apr 12, 2017
Timothy Coughlin	Feb 8, 2017	137,961 shares, last reported balance as of Feb 6, 2017
David-Alexandre Gros	Feb 8, 2017	No balance on record
Thomas Mitchell	May 24, 2016	2,000 shares, last reported balance as of Jun 23, 2015
BVF PARTNERS L P/IL	Feb 10, 2012	46,121,630 shares, last reported balance as of Feb 9, 2012
Jensen Valeur	Sep 1, 2011	118,256 shares, last reported balance as of Feb 28, 2011
Wylie Vale	May 25, 2011	505,597 shares, last reported balance as of Mar 3, 2006
VENROCK HEALTHCARE CAPITAL PARTNERS LP	Jan 5, 2010	4,784,689 shares, last reported balance as of Dec 22, 2009
Bryan Roberts	Jan 5, 2010	4,784,689 shares, last reported balance as of Dec 22, 2009
Richard Ranieri	Feb 29, 2008	9,667 shares, last reported balance as of Feb 12, 2008
Paul Hawran	Sep 20, 2006	360,144 shares, last reported balance as of May 17, 2006
Adrian Adams	Jun 30, 2006	No balance on record
Wendall Wierenga	Jan 23, 2006	5,023 shares, last reported balance as of Oct 10, 2003
Henry Pan	Jun 6, 2005	11,216 shares, last reported balance as of Mar 1, 2004
Lawrence Steinman	Mar 2, 2005	15,500 shares, last reported balance as of Mar 2, 2005
Robert Little	Feb 22, 2005	No balance on record
Cynthia Thomas	Mar 3, 2004	4,670 shares, last reported balance as of Mar 1, 2004
John Saunders	Dec 19, 2003	2,916 shares, last reported balance as of Dec 18, 2003
Paul Conlon	Dec 18, 2003	57,335 shares, last reported balance as of Dec 16, 2003
Bruce Campbell		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Neurocrine Biosciences Inc insiders sold $77.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Neurocrine Biosciences Inc CEO selling stock?

Why are Neurocrine Biosciences Inc insiders selling?

Are any Neurocrine Biosciences Inc insiders buying?

The evidence

Taxes

Charitable gifts · 12K shares

Sales by month